Locally advanced prostate cancer comprises approximately 20% of new prostate cancer
diagnoses. For these patients, international guidelines recommend treatment with …

The majority of patients with prostate cancer who later develop lethal metastatic disease
have high-risk localized disease at presentation, emphasizing the importance of effective …

Context Several recent randomised trials have evaluated the role of combination systemic
treatment using androgen deprivation therapy (ADT) plus chemotherapy or an androgen …

Background Intensification of therapy may improve outcomes for patients with high-risk
localized prostate cancer. Objective To provide long-term follow-up data from phase III …

PURPOSE Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard
treatment option for patients with high-risk localized prostate cancer. We hypothesized that …

Advanced prostate cancer is a continuum of states distinguished by the presence or
absence of metastasis and sensitivity or resistance to androgen deprivation therapy (ADT) …

Context Systemic therapies, combined with local treatment for high-risk prostate cancer, are
recommended by the international guidelines for specific subgroups of patients; however, for …

Background Intensification of therapy may improve outcomes for patients with high-risk
localized prostate cancer. Objective To provide long-term follow-up data from phase III …

The standard treatment options based on the risk category for non-metastatic prostate
cancer include surgery, radiotherapy, and watchful waiting (and more recently, active …

High-risk prostate cancer is a heterogeneous group that includes patients with clinically
locally advanced stage disease at diagnosis. Unlike overt locally advanced disease …